Journal
ONCOGENE
Volume 29, Issue 35, Pages 4865-4873Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.222
Keywords
Fbw7; ubiquitin-proteasome system; GSK-3 beta; p53
Funding
- National Institutes of Health [RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, P30CA016087]
- American Cancer Society [RSG0806801]
- Edward Mallinckrodt Jr Foundation
- Irma T Hirschl Trust
- Alex's Lemonade Stand Foundation
- NYU [5T32CA009161]
- NATIONAL CANCER INSTITUTE [R01CA133379, T32CA009161, R21CA141399, R01CA149655, R01CA105129, P30CA016087] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined. Oncogene (2010) 29, 4865-4873; doi: 10.1038/onc.2010.222; published online 14 June 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available